Nephrology Drugs Market Report 2026

Nephrology Drugs Market Overview

• Nephrology Drugs market size has reached to $17.69 billion in 2025 • Expected to grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Addressing The Silent Epidemic The Growing Prevalence Of Chronic Kidney Disease Fuels Expansion In The Nephrology Drugs Market • Market Trend: FDA Approval Of Jardiance (Empagliflozin) Marks A Milestone In Nephrology Drugs Market • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Nephrology Drugs Market?

Nephrology drugs, also known as renal drugs, refer to medicines related to kidney care. These drugs are often related to high blood pressure and hypertension. It is used to attempt to enhance kidney function and to slow the disease down, preventing it from doing further harm to the body. The main types of drugs used in nephrology drugs are antihypertensive agents, erythropoiesis-stimulating agents, diuretics, ACE inhibitors, antidiabetic agents, and other drugs. Antihypertensive agents refer to a class of drugs used to treat high blood pressure. Antihypertensive medications come in a wide variety and have several mechanisms of action for high blood pressure. These drugs are consumed through different routes of administration, such as oral, parenteral, and other routes of administration, it is distributed through hospital pharmacies, online pharmacies, and retail pharmacies. And major end-users are hospitals, homecare, specialty clinics, and other end-users.

What Is The Nephrology Drugs Market Growth Forecast?

The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to $24.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to development of precision medicine for nephrology, integration of ai in renal drug development, expansion of homecare treatment solutions, rising investment in biotechnology for kidney therapies, adoption of digital health monitoring for kidney patients. Major trends in the forecast period include personalized kidney care solutions, rising prevalence of hypertension-related kidney disorders, advancements in renal drug formulations, growing awareness of chronic kidney disease management, increased adoption of home-based renal treatments.

What Is The Driver Of The Nephrology Drugs Market?

The rising prevalence of chronic kidney disease is expected to propel the growth of the nephrology drugs market going forward. Chronic kidney disease (CKD) refers to damaged kidneys that are unable to filter blood as effectively as they should. because kidney damage develops gradually over a lengthy period of time. Wastes could accumulate in the body as a result of this injury. Nephrology drugs are primarily used in the treatment of chronic kidney disease to enhance kidney function and slow the disease, preventing it from doing more harm to the body, so these factors boost the nephrology drug market. For instance, in June 2023, according to the Oxford Academic, a UK-based Oxford University Press's academic research platform, the prevalence of CKD in the UK is projected to rise by 4% from 8.27 million to 8.61 million people between 2022 and 2032, with stage distribution in 2032 expected at 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the nephrology drug industry.

Key Players In The Global Nephrology Drugs Market

Major companies operating in the nephrology drugs market are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Mylan N.V.

Global Nephrology Drugs Market Trends and Insights

Major companies operating in the nephrology drugs market are focusing on approvals for innovative products, such as the U.S. Food and Drug Administration approval of Jardiance (empagliflozin), to better meet the needs of their existing consumers. Empagliflozin is a diabetic medicine used to control and treat type 2 diabetes mellitus. It belongs to the sodium-glucose co-transporter (SGLT-2) family of diabetic medicines. Empagliflozin reduces blood sugar levels by forcing the kidneys to excrete more glucose in the urine. For instance, in January 2023, Eli Lilly and Company, a US-based pharmaceutical company, and Boehringer Ingelheim announced that the Food and Drug Administration approved a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which are being studied as a potential treatment for lowering the risk of advancing kidney disease and cardiovascular death in adults with chronic kidney disease (CKD). Boehringer Ingelheim is a Germany-based pharmaceutical company.

What Are Latest Mergers And Acquisitions In The Nephrology Drugs Market?

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics for an undisclosed amount. This acquisition underscores Novartis' commitment to expanding its portfolio in the renal market, particularly in Greater China and Singapore, where there is significant potential for growth in nephrology therapeutics. The strategic move also aligns with Novartis' broader goals of pioneering innovative treatments for kidney diseases, enhancing its competitive position within the nephrology drugs market. SanReno Therapeutics is a China-based clinical-stage biotechnology company focused on developing innovative therapies for kidney diseases, particularly Immunoglobulin A Nephropathy (IgAN).

What Defines the Nephrology Drugs Market?

The nephrology drugs market consists of sales of invokana, phoslo, renvela, sensipar, and procrit drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nephrology Drugs Market Report 2026?

The nephrology drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.